Literature DB >> 1362394

A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group.

.   

Abstract

On the long term Parkinson Disease (PD) treatment is often complicated by the occurrence of motor fluctuations. To find out whether early treatment of PD with levodopa, dopaminoagonists or l-deprenyl is associated with any difference in motor fluctuations occurrence, the Italian Parkinson Study Group initiated a multicenter, randomized study. Since November 1988, 475 patients requiring effective treatment for idiopathic PD have been randomized to receive levodopa, dopamine agonists or deprenyl. After 2 months of therapy, all patients evaluated with the Unified Parkinson Disease Rating Scale showed a significant amelioration. Daily living activities were more impaired in patients treated with deprenyl. Study design is presented and first results are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362394     DOI: 10.1007/bf02229158

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  12 in total

1.  Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out.

Authors:  W M Landau
Journal:  Neurology       Date:  1990-09       Impact factor: 9.910

Review 2.  Parkinson's disease.

Authors:  C D Marsden
Journal:  Lancet       Date:  1990-04-21       Impact factor: 79.321

3.  Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease.

Authors:  E Melamed
Journal:  Arch Neurol       Date:  1986-04

4.  Effect of deprenyl on the progression of disability in early Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

5.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Authors:  J W Tetrud; J W Langston
Journal:  Science       Date:  1989-08-04       Impact factor: 47.728

6.  Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.

Authors:  T S Elizan; M D Yahr; D A Moros; M R Mendoza; S Pang; C A Bodian
Journal:  Arch Neurol       Date:  1989-12

7.  Multi-center study of Parkinson mortality with early versus later dopa treatment.

Authors:  S G Diamond; C H Markham; M M Hoehn; F H McDowell; M D Muenter
Journal:  Ann Neurol       Date:  1987-07       Impact factor: 10.422

8.  Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

Authors:  G Cohen; P Pasik; B Cohen; A Leist; C Mytilineou; M D Yahr
Journal:  Eur J Pharmacol       Date:  1984-10-30       Impact factor: 4.432

9.  The heterogeneity of Parkinson's disease: clinical and prognostic implications.

Authors:  W J Zetusky; J Jankovic; F J Pirozzolo
Journal:  Neurology       Date:  1985-04       Impact factor: 9.910

10.  Mortality associated with early and late levodopa therapy initiation in Parkinson's disease.

Authors:  G Scigliano; M Musicco; P Soliveri; I Piccolo; F Girotti; P Giovannini; T Caraceni
Journal:  Neurology       Date:  1990-02       Impact factor: 9.910

View more
  4 in total

Review 1.  Parkinson's disease.

Authors:  Carl E Clarke; A Peter Moore
Journal:  BMJ Clin Evid       Date:  2007-08-01

Review 2.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

Review 3.  Monoamine oxidase B inhibitors for early Parkinson's disease.

Authors:  A D Macleod; C E Counsell; N Ives; R Stowe
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

Review 4.  Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis.

Authors:  Chuanjun Zhuo; Rong Xue; Lanlan Luo; Feng Ji; Hongjun Tian; Hongru Qu; Xiaodong Lin; Ronghuan Jiang; Ran Tao
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.